Who we are
Creating a new international ophthalmic company
Nicox is a new international player in the ophthalmic market building a diversified portfolio of innovative therapies and diagnostic tools addressing the needs of eyecare practitioners and patients around the world.
Our global growth strategy is focused on outstanding international collaborations and on our proprietary nitric oxide-donating research platform.
We are actively seeking and evaluating commercial and late-stage ophthalmic products as well as potential acquisitions of local ophthalmic companies in Europe’s largest markets.
An innovative portfolio in the ophthalmic field
Latanaprostene bunod, in Phase 3 for glaucoma
The Company’s pipeline includes latanoprostene bunod, a novel drug-candidate based on Nicox’s proprietary nitric oxide (NO)-donating research platform, developed in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Following positive phase 2b results, Bausch + Lomb initiated a phase 3 program for latanoprostene bunod in January 2013.
Diagnostic tests marketed by Nicox
In the United States, Nicox's sales force promotes two diagnostic tests to eye care practitioners:
- AdenoPlus®, a point-of-care test that aids in the differential diagnosis of acute conjunctivitis (in-licensed from Rapid Pathogen Screening, Inc., RPS®). AdenoPlus® is CE-marked and is available for sale by Nicox or its distributors in Europe and other countries.
- Sjö™, an advanced diagnostic for the early detection of Sjögren’s Syndrome in patients with dry eye symptoms (exclusive North American agreement with Immco Diagnostics Inc). Sjö™ is not available in the rest of the world, including Europe.
A world-leading position in Nitric Oxide research
We have developed a leading position in the therapeutic application of novel NO-donating compounds based on our strong proprietary research platform.
The Company’s Research subsidiary is focusing its efforts in the ophthalmic field and is working in collaboration with Universities and Research institutions on several compounds for ocular disorders.
Nicox is also partnering with pharmaceutical companies, such as Bausch + Lomb and Merck (known as MSD outside the United States and Canada), to further advance programs and develop promising NO-donating new molecular entities.Our pipeline shows our development projects in the ophthalmic field and in other therapeutic areas.
Nicox across the globe
Nicox is headquartered in Sophia Antipolis (Nice, France) and is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX). North American operations are based in Fort Worth (Texas, United States) and research capabilities in Bresso (Milan, Italy). Nicox employs around 50 people worldwide.
Nicox has set up specialized operations and sales teams in the United States and in Europe to support its planned growth in these markets. In parallel, the Company is establishing partnerships with local distributors for other important markets across the world.